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Cdk5 Is a Key Factor in Tau Aggregation
and Tangle Formation In Vivo
as candidates in pathogenic tau phosphorylation. The
activity of cdk5 is regulated by its binding with neuron-
specific activator proteins p35, p25, and p39. Cleavage
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activity affects the progression of tau pathology, we
crossed mice with enhanced endogenous cdk5 activitySummary
to mice with mutant human tau. Double transgenic mice
showed enhanced hyperphosphorylation and aggrega-Tau aggregation is a common feature of neurodegen-
erative diseases such as Alzheimer’s disease, and tion of tau, and increased tangle formation compared
to single transgenic tau mice. Cdk5 may act directly,hyperphosphorylation of tau has been implicated as
a fundamental pathogenic mechanism in this process. indirectly, or in concert with GSK3 as this kinase was
also overactive in the double transgenic mice, and colo-To examine the impact of cdk5 in tau aggregation and
tangle formation, we crossed transgenic mice overex- calized with both aggregated tau and cdk5. This study
shows that although previous studies suggest activationpressing the cdk5 activator p25, with transgenic mice
overexpressing mutant (P301L) human tau. Tau was of cdk5 is not sufficient to initiate tangle formation in
mice, increased activity of cdk5 greatly enhances neuro-hyperphosphorylated at several sites in the double
transgenics, and there was a highly significant accu- fibrillary pathology development. Thus inhibitors of cdk5
activity may have utility in ameliorating the pathologymulation of aggregated tau in brainstem and cortex.
This was accompanied by increased numbers of sil- of AD.
ver-stained neurofibrillary tangles (NFTs). Insoluble
tau was also associated with active GSK. Thus, cdk5 Results
can initiate a major impact on tau pathology progres-
sion that probably involves several kinases. Kinase P25 Overexpression Is Associated
inhibitors may thus be beneficial therapeutically. with Enhanced Cdk5 Activity
P25 transgenic mice were derived from mice overex-
Introduction pressing the human p25 cDNA in neurons (Ahlijanian et
al., 2000). Hemizygous mice were crossed with mice
Neurofibrillary tangles (NFTs) are a common feature of expressing mutant human tau (P301L, 4R0N) (Lewis et
many neurodegenerative diseases, including Alzhei- al., 2000) and progeny were genotyped as tau (T), p25,
mer’s disease (AD). Human NFTs are composed primar- p25/T double transgenic, and nontransgenic (Ntg).
ily of aggregated tau in paired helical filaments (PHF) Alteration in the ratio of p25:p35 through increased
which are hyperphosphorylated at several sites (Grundke- production of the activator p25 is associated with en-
Iqbal et al., 1986; Friedhoff et al., 2000). Hyperphosphor- hanced cdk5 activity in humans (Lew et al., 1994). Trans-
ylation of tau has been suggested to be a pathogenic genic mice overexpressing either p35 or p25 have been
process that may impact the initiation, or progression of created to attempt to enhance the in vivo activity of
tauopathy. Several kinases, including the proline-directed, cdk5, but only the p25 mice have an obvious phenotype
cyclin-dependent kinase-5 (cdk5), have been implicated (Ahlijanian et al., 2000; Bian et al., 2002). In general, p25
overexpression in mice enhanced cdk5 activity 2- to
5-fold. Although there was no hyperphosphorylation of*Correspondence: duff@nki.rfmh.org
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Figure 1. P25 Expression, Cdk5 Activity, and
Tau Hyperphosphorylation in p25/T Mice
Western blot analysis showing p35 and p25
expression in p25/T, T, p25, and Ntg mice.
P25 expression was greatly increased relative
to p35 in p25 transgenic animals (A). Western
blot analysis of cdk5 levels in the amygdala
showed that p25 transgenic animals did not
show a higher level of cdk5 when compared
to littermate controls (B). Kinase activity
assays showed an approximately 2-fold in-
crease in cdk5 activity in the amygdala of p25
transgenic mice (C) (p25/T versus T and p25
versus Ntg). Tau ELISA (D) showed hyper-
phosphorylation of tau in the amygdala of
p25/T mice compared to T at epitopes S202 and
S396/404. There was no significant increase in
the relative phosphorylation level in p25 sin-
gle transgenics compared to Ntg mice. **p 
0.005; n  5–8 in all analyses.
tau, tau was phosphorylated at several sites in select assays demonstrated that cdk5 activity in this area was
increased approximately 2-fold (p  0.05; Figure 1C) inneurons, and axonopathy and tau accumulation in the
form of spheroids resulted, especially in the amygdala. the same mice. P301L transgene overexpression and
the phenotype it confers is not associated with alteredAlthough early generations of p25 mice supplied to us
developed spheroids, p25 mice in this study had lost the cdk5 activity, as there was no significant difference in
activity levels between single transgenic P301L micespheroid phenotype, presumably due to genetic drift.
Western blot analysis of p35/p25 levels showed that as and nontransgenic littermates (T versus Ntg) or between
p25/T mice and single transgenic p25 mice (p25/T ver-expected, p25 was significantly enhanced in transgenic
mice expressing the p25 transgene (Figure 1A), but p35 sus p25). Endogenous tau in p25 mice was not hyper-
phosphorylated compared to Ntg mice in total brainlevels were unchanged. Immunoblotting with anti-cdk5
antibodies showed that the level of cdk5 in the same homogenate from this region, as demonstrated pre-
viously by immunoblot analysis of this line (Ahlijanianregion (amygdala) of p25 overexpressing mice (p25/T
and p25) was not altered when compared to controls et al. 2000). There was, however, a trend to increase,
especially for tau phosphorylated at S396/404 (Figure 1D).(Ntg and T mice, Figure 1B). However, kinase activity
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Figure 2. Analysis of Heat Stable Tau
There was a significant increase in the
amount of total human (CP27) and mouse/
human (TG5) in p25/T mice compared to T
(A). Hyperphosphorylation was observed at
cdk5-directed sites S202, S396/404, T181, and T231 in
p25/T when normalized to CP27 levels. ELISA
analysis of total tau levels confirmed the
Western blot analysis for total tau levels (B)
and phospho-tau (C). These data suggest
that cdk5 phosphorylates free, unaggregated
tau. ***p 0.0005, **p 0.005, *p 0.05; n
5–8 in each group.
Enhanced Cdk5 Activity Is Associated Cdk5 Overactivity Is Associated with Increased
Aggregation of Tau in p25/T Micewith Increased Tau Hyperphosphorylation
in p25/T Mice We next examined whether cdk5 overactivity promoted
aggregate formation in two regions, the cortex and theIn heat-stable tau preparations, antibodies recognizing
both human tau (CP27) and total tau (mouse/human, hindbrain. Three fractions were prepared: total lysate
after a low-speed spin (LSS) which contains all proteins,TG5) showed an increase in tau in p25/T mice compared
to T mice (p  0.005 for CP27, p  0.05 for TG5) when supernatant after addition of sarkosyl and a high-speed
spin (HSS), and the sarkosyl-insoluble pellet (SP) whichassessed by immunoblot (Figure 2A) and ELISA (Figure
2B). Phosphorylation of tau was enhanced at putative is highly enriched for aggregated tau.
Immunoblot and ELISA analysis was performed on thecdk5-directed sites S202, S396/404, T181, and T231 (Liu et al.,
2002; Hashiguchi et al., 2002) in p25/T mice relative to LSS (Figure 3) and SP (Figure 4) fractions. Quantitative
analysis of LSS showed an increase (p 0.05) in humanT (Figure 2A). When normalized to either CP27 or TG5,
there was a significant increase in phosphorylation (hy- tau in the brainstem by immunoblotting (Figure 3A) and
ELISA (Figure 3C), but not the cortex of p25/T miceperphosphorylation) at these sites (p  0.05 for all).
ELISA confirmed the results of immunoblot analysis compared to T mice (Figures 3B and 3C). When normal-
ized to human tau, there was a significant increase in(Figure 2C).
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Figure 3. Regional Hyperphosphorylation of
Tau in p25/T Mice
Levels of total and phosphorylated (S202 and
S396/404) tau were increased in the brainstem
lysate from p25/T mice when assessed by
immunoblotting (A). There was no increase in
total tau levels in the cortex (B), with hyper-
phosphorylation detected only at S202, sug-
gesting that the brainstem hyperphosphory-
lation is more advanced. The increase in total
tau was also significant in the brainstem, but
not the cortex when assessed by ELISA (C).
When ELISA data was normalized to levels
of total tau (CP27), S202 was significantly hy-
perphosphorylated in the brainstem and cortex
of p25/T mice, while phosphorylation at S396/404
was only significantly increased in the brain-
stem (D). **p  0.005; *p  0.05; ns, p  0.05;
n  5–8 in each group.
tau hyperphosphorylated at S202 in p25/T mice relative immunoblotting and ELISA showed that aggregated, hu-
man tau was significantly increased in the SP of brain-to T mice in both the brainstem and cortex (p  0.05
for both; Figures 3A, 3B, and 3D). In the brainstem of stem and cortex from double transgenics (p  0.005,
p 0.05, respectively; Figures 4B–4G). No tau was iden-p25/T mice, there was also a significant increase in tau
hyperphosphorylated at S396/404 compared to T mice (p tified in the SP fraction from p25 or Ntg animals (data
not shown). Both p25/T and T mice had tau in the SP that0.05; Figures 3A and 3D), but this was not seen in the
cortex (p  0.05; Figures 3B and 3D). migrated at approximately 53 kDa. Tau from p25/T mice
had an additional form that migrated at approximatelyTau from the sarkosyl pellet is regarded as filamen-
tous, aggregated, and synonymous with that identified 64 kDa (Figures 4B and 4C, arrows). The lower mobility
band was highly immunoreactive with CP13 (S202) in theby immunohistochemistry in NFTs. To confirm this, we
identified phospho-S396/404 immunoreactive filaments in brainstem (Figure 4B), whereas the 53 kDa was the pre-
dominantly labeled band in the cortex, with a smallthe brainstem SP of both p25/T and T mice by immuno-
gold labeling and electron microscopy (Figure 4A). No amount of the 64 kDa band being visible (Figure 4C).
Overall, there was a significant increase in pS202 tau inqualitative differences were identified in tau filaments
from the two mouse groups. Filaments identified were the SP of the brainstem assessed by immunoblotting
and ELISA (Figures 4B and 4D).very similar to those described previously in the tau
P301L mouse—mainly straight, with a diameter of be- Phospho-S396/404 was detected in both bands in the
brainstem and cortex of p25/T mice (Figures 4B andtween 10 and 30 nm (Lewis et al., 2000). Quantitative
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4C), but there was relatively little of the 64 kDa tau gions, but also to some extent in the amygdala.
Immunopositive neurons were only occasionally foundisoform in the brainstem of T mice. Both assessment
methods showed a significant difference for S396/404 in in the cortex. NFTs were identified by Thioflavin S and
Gallyas silver stain mainly in the spinal cord (Lewis etthe brainstem of the p25/T mice compared to T (Figures
4B and 4D), but not in the cortex (Figures 4C and 4E), al., 2000). To assess whether doubly transgenic p25/T
mice derived from this line had increased numbers ofalthough the contribution of the 64 kDa form of phos-
phorylated tau could only be appreciated on the immu- NFTs in addition to increased hyperphosphorylated, ag-
gregated tau as a result of elevated kinase activity, thenoblot. When the amount of aggregated, phospho-tau
in the SP was normalized to the amount of tau in the number of Gallyas silver-positive neurons in the brain-
stem of p25/T and T mice were counted. We found aLSS, there was a striking increase in the proportion of tau
aggregated in the brainstem of p25/T mice compared to highly significant increase in the number of NFTs in the
brainstem of p25/T mice relative to T controls (FigureT controls (Figure 4F). In the brainstem of p25/T mice, the
increased phosphorylation observed in the proportion of 6; p  0.05), which correlates with the results of the
biochemical analyses. Gallyas-positive neurons weretau that has aggregated reflects the greater proportion
of lower mobility tau (64 kDa band). The effect of p25/ not found in p25 or Ntg mice (data not shown).
cdk5 on aggregation in the cortex was not as profound.
Although the proportion of total aggregated tau was Discussion
increased in p25/T mice (Figure 4G), it was not signifi-
cantly more hyperphosphorylated. However, it is clear The most striking finding of this study was the dramatic
from the immunoblots that a proportion of the phospho- increase in sarkosyl-insoluble, hyperphosphorylated,
tau aggregated in the cortex of p25/T mice has under- aggregated tau in double transgenic mutant tau mice
gone a mobility shift not observed in the T mice. The with enhanced endogenous cdk5 activity, compared to
reciprocal results were observed in the HSS (data not age, stage, and gender-matched tau mutant mice with
shown), with reduced levels of sarkosyl-soluble, unag- normal activity of cdk5. The use of a transgenic mouse
gregated, hyperphosphorylated tau observed in p25/T with increased levels of the activator p25 that has normal
mice. levels, but enhanced activity of endogenous cdk5,
makes this a particularly good in vivo system in which
Both Cdk5 and GSK3 Are Associated to study the impact of cdk5 in initiating events involved
with Aggregated Tau in the Brainstem in enhancing pathogenesis.
We previously showed that the level of cdk5 was un- We have shown that tau is hyperphosphorylated at
changed in p25/T mice compared to T controls, whereas several sites including S202, T181, T231, and S396/404 in heat-
its activity was significantly increased (Figures 1B and stable tau preparations from p25/T mice. As these prep-
1C). Similarly, we have also determined that the protein arations are free of tau aggregates, this suggests that
level of GSK3/ was unchanged, but its activity was cdk5, or downstream kinases, can phosphorylate tau
increased in total lysate from p25/T mice compared to prior to, or independently of, aggregation. Aberrant
T controls (Figure 5A). We next examined total and active phosphorylation at the sites identified has been sug-
forms of cdk5 and GSK3 associated with aggregated gested to lead to a significant reduction in the affinity
tau in the brainstem SP fraction of p25/T and T mice of tau for microtubules, and its ability to stabilize them
(Figure 5B). Total and active forms of cdk5 were associ- (Biernat et al., 1993; Sengupta et al., 1998). The reduced
ated with aggregated tau from p25/T and T mice. GSK3 affinity of phosphorylated tau for microtubules could
and its activated forms, especially the GSK3 and 2 increase the amount of unbound cytoplasmic tau as
isoforms, were also identified in the SP fraction from shown by the increased levels of CP27 and TG5. In vivo,
p25/T mice, but they were negligible in aggregated tau phosphorylated tau polymerizes faster than it can be
preparations from T mice (Figure 4B). The presence of degraded (Billingsley and Kinkaid, 1997), which may also
these kinases in the SP fraction indicates that both of account for the increase in total tau we have observed.
these kinases are strongly bound with tau that is aggre- Once unbound tau reaches a critical level, it is more
gated. Confocal microscopy was performed to demon- prone to fibrillization, which would encourage the in-
strate that the activated kinases colocalize with tau in creased aggregation we have demonstrated in the p25/T
neurons (Figure 5C). Phospho-GSK3 (Figure 5C, green) mice. This is supported by previous studies which have
colocalized with human tau in its abnormal AD-relevant shown that tau hyperphosphorylation promotes the self-
conformation (recognized by MC1, red) mainly in the assembly of filamentous tau (Alonso et al., 2001). Inter-
cell body (overlap shown in yellow), although some pro- estingly, we have also found activated kinases in associ-
cesses were also immunolabeled. Cdk5 and tau also ation with aggregated tau, suggesting that these kinases
overlapped throughout the soma, and processes were continue to phosphorylate tau once tangle formation has
prominently labeled. We were also able to show a degree begun. These findings are in agreement with previous
of colocalization between cdk5 and GSK3/ in neurons. immunohistochemical studies which have shown a
strong association between NFTs, cdk5, and/or GSK3
(Baumann et al., 1993; Paudel et al., 1993; YamaguchiOveractivity of Cdk5 Enhances the Development
of NFTs in p25/T Mice et al., 1996; Pei et al., 1997).
The increase in aggregated tau in the brainstem regionFemale tau P301L mice at 12 months of age have been
shown to develop neuronal cell body staining for phos- of p25/T mice was more pronounced than in the cortex,
most likely due to the high level of human tau expression,pho-tau (pS202 and pS396/404) and for conformationally ab-
normal tau mainly in the spinal cord and brainstem re- and/or increased vulnerability of this region reported for
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Figure 5. Association of Cdk5 and GSK3 with Aggregated Tau
Western blot analysis of GSK3 levels in total lysate. There was no increase in the total protein level of GSK3  or , but the active form of
GSK3 (Y216), but not gsk3 (Y279), was increased in p25/T mice (A). Both cdk5 and GSK3 and their active forms were detected in association
with aggregated tau (B). Cocal microscopy demonstrated colocalization of the active forms of these kinases with MC1-positive tau, and
colocalization of cdk5 and GSK3 with each other (C). Scale bar, 50 m.
the parental tau P301L mouse line (Lewis et al., 2000). whereas S396/404 hyperphosphorylation occurs later (Au-
gustinack et al., 2002). Brain regions without motor neu-The brainstem appeared to be at a later stage in pathol-
ogy progression as indicated by the presence of higher rons (e.g., cortex) also have increased hyperphosphory-
lated/aggregated tau compared to the single taumolecular weight tau forms and the increase in tau hy-
perphosphorylated at S396/S404. Hyperphosphorylation at transgenics, suggesting that tangle distribution does
shift (or extend) in the double transgenics.T181, S202, and T231 are thought to be early events in NFT
formation, indicative of the presence of pretangle tau, In the mice studied, enhanced brainstem neurofibril-
Figure 4. Cdk5 Enhances Tau Aggregation
Immunogold staining of EM sections ( 21,000 magnification) showing tau filaments immunoreactive with PHF1 were present in the sarkosyl
pellet (A). The level of sarkosyl-insoluble, aggregated tau was increased in both the brainstem (B) and cortex (C) of p25/T mice when assessed
by immunoblotting. Tau forms of 53 kDa (line) and 64 kDa (arrow) were observed. When assessed by ELISA, there was a significant increase
in total tau and tau phosphorylation at S202 in the brainstem (D) and cortex (E) and at S396/404 in the brainstem alone (D). The proportion of
aggregated tau:total tau was greatly increased in p25/T mice in both brainstem (F) and cortex (G). ***p  0.0005; **p  0.005; *p  0.05; ns,
p  0.05; n  5–10 in each group.
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Figure 6. Cdk5 Enhances the Development of Neurofibrillary Pathology
Quantitative analysis of the number of Gallyas silver-stained neurons in the brainstem of p25/T and T mice showed a 3- to 4-fold increase in
the number of tangles in double transgenic p25/T mice compared to matched T controls (A). Typical brainstem area in p25/T mice (B) and
representative section from T mice brainstem (C). Higher power images showing Gallyas-stained neurofibrillary tangles present in p25/T mice
are shown in (D) and (E). Scale bar, 10 m (B and C) and 50 m (D and E); **p  0.005; n  7–10 in each group.
lary pathology in p25/T mice was not associated with complex of kinases, substrates, and regulators is pres-
ent in tangle-bearing neurons.significantly accelerated dystonia (Lewis et al. 2000) that
normally starts in tau P301L-derived mice at 12–14 Although both cdk5 and GSK3 are known to phos-
phorylate murine tau in p25 or GSK3 overexpressingmonths of age (data not shown). Both p25/T and T mice
used in this study were matched in terms of their stage transgenic mice respectively, no increase in insoluble
tau aggregates or tangles were observed, although thereof dystonia, with both groups being considered unaf-
fected, or marginally affected when assessed for degree was evidence of axonal dysfunction (Ahlijanian et al.,
2000; Spittaels et al., 2000; Lucas et al., 2001; Bian etof paralysis (data not shown). It is possible that any
acceleration in outwardly visible degeneration was too al., 2002). This suggests that in mice, low-level phos-
phorylation of axonally distributed, normal tau is notsubtle to be identified in this study, but mice aged be-
yond 1 yr are not yet available. sufficient to initiate tangle formation. Confusingly, in a
double transgenic human tau/GSK3 overexpressingStudies have implicated cdk5 as a candidate kinase
for early tau hyperphosphorylation due to its axonal lo- mouse, axonal pathology and spheroids were de-
creased compared to the single transgenic tau controlcalization (Ishiguro et al., 1995). Inhibition of cdk5 activ-
ity specifically inhibits fast anterograde axonal transport (Spittaels et al., 2000), but aggregated tau formed in
the omatidia of a double transgenic, human tau/GSK3and redistribution of cellular proteins (Ratner et al.,
1998). GSK3 is thought to be associated with neurofi- overexpressing Drosophila model (Jackson et al., 2002).
The significant differences between all these models inbrillary changes (Yamaguchi et al., 1996; Pei et al., 1997;
Planel et al., 2002), particularly in later-stage phosphory- terms of species/strain (mouse, fly), kinase type and
distribution (cdk5, GSK3, processes, or cell body), taulation of tau as this kinase is associated with microtu-
bules in the cell body, which would bring it into contact type and distribution (endogenous murine tau or human
tau overexpressor, axonal, or somatodendritic distribu-with tau once it has redistributed to the somatodendritic
portion of the cell (Flaherty et al., 2000). In the p25/T tion), and cell type (motor neurons, cortical/hippocam-
pal neurons, or sensory neurons) makes it difficult tomice, overactivity of cdk5 over a long period of time
could not only enhance the redistribution of tau into the extrapolate the relevance of the results to human tau
pathogenesis. In terms of the contribution of cdk5 tocell body which occurs in tau overexpressing mice, but
also increase the “priming” of tau for subsequent phos- pathogenesis in a mouse model with tangles that are
highly relevant to human tauopathy, we have providedphorylation by GSK3 (Ishiguro et al., 1995; Sengupta
et al., 1997). The colocalization of active cdk5 and tau compelling evidence that cdk5 overactivity can promote
tau aggregation and tangle formation, with concomitantin the soma and processes, and GSK3 and tau mainly
in the soma of our mice, supports this idea and is consis- hyperphosphorylation, thereby enhancing the develop-
ment of neurofibrillary pathology in mice predisposedtent with tau/kinase observations in other tau transgenic
mice (Yamaguchi et al., 1996; Pei et al., 1997; Flaherty to tauopathy. The p25 mice do not have insoluble tau
nor do they have Gallyas silver-stained neurons (dataet al., 2000; Gotz and Nitsch, 2001). We have also shown
that cdk5 and GSK3/ colocalize within neurons of our not shown), so the phenotype seen in the p25/tau mice
is not the result of overlain pathologies, but interactivemice, and it is likely that both kinases, together with
other putative tau kinases, are involved in NFT formation pathways. Importantly, this occurs both in the brain-
stem, and in cortex—a region not usually affected in tauand/or progression (Veeranna et al., 2000; Gotz and
Nitsch, 2001; Williamson et al., 2002). We have deter- P301L mice that is of significant importance in dement-
ing diseases.mined that both active cdk5 and GSK3 are associated
with tau in an abnormal conformation (MC1 immunore- The neuropathology of AD is characterized not only
by NFTs but also by extracellular amyloid plaques com-active) by immunohistochemistry, and that both active
and inactive kinases are associated with aggregated tau posed mainly of aggregated A peptides. Several stud-
ies have shown that A influences tau kinase activity infractions, supporting the theory that a macromolecular
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and 1 mM sodium orthovanadate. The homogenates were centri-vitro (Takashima et al., 1993; Tomidokoro et al., 2001;
fuged at 15,000g for 20 min, and resultant supernatants were usedRank et al., 2002), and Town et al. (2002) describe a
for the assay. Protein concentration was determined and adjusted tomechanism whereby A induces tau hyperphosphoryla-
0.7 g/l. Protein samples were serially diluted, and 50 l of diluted
tion via the cdk5 pathway. It has been shown that cal- sample was applied to a coated Maxi-Sorb ELISA plate (Nalgene,
pains (which increase cdk5 activity by increasing cleav- Nunc International, Roskilde, Denmark). After samples were evapo-
rated to dryness, the plates were blocked in TBS containing 5%age of p35 to p25) are upregulated in AD brain (Grynspan
nonfat dry milk for 1 hr at room temperature. Tau antibodies wereet al., 1997; Tsuji et al., 1998; Lee et al., 2000), and recent
used at 1:200 dilution and were incubated overnight at 4C. Platesstudies have shown that elevated A enhances tangle
were washed with 50 mM TBS containing 0.5% Tween 20 5. Boundformation in mutant tau mice (Lewis et al., 2001; Gotz
antibodies were detected using HRP-coupled secondary antibodies
et al., 2001). This suggests that the induction of signal and visualized using a kit (TMB Microwell Peroxidase Substrate
transduction pathways by A enhances neurofibrillary System; Kirkengaard & Perry Laboratories, Gaithersburg, MD). O.D.
was calculated using a Bio-Kinetics Reader EL312e (Bio-Tek Instru-pathology, although this may only occur in mice predis-
ments, Winooski, VT). The hyperphosphorylation status of tau wasposed to it. Neither our study nor other in vivo studies
calculated by normalizing the amount of phosphorylated to theusing the P301L mice show causality or initiation of
amount of total tau.pathogenesis as the mice start life with abnormal tau,
but the data suggest that intervention using kinase inhib-
Immunoblot Analysis of Heat Stable Tau
itors may at least ameliorate the progression of neurofi- Mouse amygdala samples were homogenized with a polytron ho-
brillary pathology in diseases such as AD. mogenizer on ice at a w/v ratio of 100 mg tissue/ml in 50 mM
Tris, pH 7.4, 0.8 M NaCl, and 5% -mercaptoethanol. Heat-stable
fractions were prepared according to the method described in DuffExperimental Procedures
et al. (2000). Samples containing 1–3g of protein were run on a 12%
Tris-tricine gel (Invitrogen, Carlsbad, CA), then electrophoreticallyTransgenic Mice
P25 transgenic mice overexpress the human p25 gene under the transferred to PVDF membrane. After blocking with 5% dry milk for
1 hr, membranes were probed with primary antibodies, detectedcontrol of the NSE promoter (Ahlijanian et al., 2000). JNPL3 trans-
genic mice with the Pro301→ Leu (P301L) tau mutation develop NFTs using HRP-coupled secondary antibodies and visualized by en-
hanced chemiluminescence reagent (SuperSignal West Pico;in the basal telencephalon, diencephalon, brainstem, and spinal
cord, along with neuronal loss that is most evident in the spinal Pierce).
cord (Lewis et al. 2000). Hemizygous p25 and JNPL3 (tau P301L)
mice were crossed and progeny were genotyped as tau (T), p25, Immunoblot Analysis of Aggregated Tau
p25/tau (p25/T), and nontransgenic (Ntg). Mice were matched for Sarkosyl extractions were performed on mouse brainstem or cortex
degree of postural dystonia, and only those graded as preparalysis/ samples according to the method of Greenberg and Davies (1990).
early stage degeneration were selected for analysis. Female mice Total brain lysate (LSS), sarkosyl-soluble (HSS), and insoluble (SP)
at 12 months of age (n  5–8) from each genotype were used for fractions were analyzed. Samples were separated on 16% Tris-
ELISA and immunoblot analysis. Mice were sacrificed by cervical tricine gels and electrophoretically transferred to PVDF membrane.
dislocation, and tissue was dissected into brainstem, amygdala/ Membranes were blocked in PBS containing 5% nonfat dry milk,
hippocampus, and cortex. Tissue was immediately snap frozen on then probed with antibodies against tau and tau kinases. Bound
dry ice. antibodies were detected using HRP-coupled secondary antibodies
(Southern Biochemicals) and were visualized by enhanced chemilu-
minescence (Pierce).Antibodies
The following monoclonal antibodies were used and specificity, iso-
type and source are given in parentheses: human tau: CP27 (mouse Electron Microscopy
IgG2b; P.D.), TG5 (220–240, mouse IgG1; P.D.); phospho-tau: CP13 Sarkosyl-insoluble tau was resuspended in sterile, filtered 10 mM
(Ser-202, mouse IgG1; P.D.), PHF1 (Ser-396/404, mouse IgG1; P.D.), TBS for EM. 5 l sample was placed on Formvar-carbon-coated
T231 (Thr-231, rabbit IgG; Biosource International, Camarillo, CA), T181 300 mesh nickel grids for 2 min and rinsed in ddH2O. After drying,
(Thr-181, rabbit IgG; Biosource); conformation-dependent tau: MC1 grids were washed for 2 min in a solution of PBS/0.1% BSA/0.1%
(5-15, 312-322, mouse IgG1; P.D.), TG3 (Ser-231, mouse IgM; P.D.); gelatin, then blocked in PBS buffer containing 5% normal goat se-
and kinases: p35 (p35 C-19, rabbit IgG; Santa Cruz Biotechnologies), rum for 10 min. Grids were incubated in phospho-tau antibody for
cdk5 (cdk5 C8, rabbit IgG; Santa Cruz Biotechnologies, Santa Cruz, 60 min at room temperature and washed. Primary antibody was
CA), cdk5 pY15 (phosphotyrosine 15 of cdk5, goat IgG; Santa Cruz detected with gold-tagged anti-mouse IgG secondary antibody
Biotechnologies), GSK3a/b (gsk3/, mouse IgG; Biosource), phos- (1/25). Samples were fixed in 2% glutaraldehyde, washed, and
pho-GSK3 (phosphotyrosine 216 of GSK3, rabbit IgG; QCB, Hop- stained with 3% aqueous uranyl acetate. The grids were examined
kinson, MA.). on a Phillips CM10 electron microscope at 80kV.
Immunoprecipitation and Cdk5 Activity Assay Gallyas Silver Stain
Immunoprecipitation and kinase assays were performed on mouse Mice were killed by cervical dislocation without perfusion, and tissue
amygdala using the NF-H-derived 14-mer peptide with two KSPXK was drop fixed in 4% paraformaldehyde in 100 mM phosphate-
repeats as enzyme substrate as described in Veeranna et al. (1996, buffered saline (pH 7.4) for 18 hr, followed by cryoprotection in 15%
1998). Briefly, the assay was performed in a total volume of a 50 l sucrose with 0.5% sodium azide overnight. Serial 30 m sections
reaction mixture containing 50 mM Tris-HCl (pH 7.4), 5 mM MgCl2, were cut using a freezing sledge microtome (Leica T2400). Silver
1 mM vanadate, 1 mM EGTA, 1 mM EDTA, 1 mM DTT, 1 mM staining was performed according to the protocol of Gallyas modi-
[	-32P]ATP, and 0.2 mM peptide substrate plus 0.1 M okadaic acid fied by Braak (Braak et al., 1988). Briefly, sections were rehydrated
or 0.1 M microcystin LR and 10 l of enzyme. The reaction was and placed in periodic acid (5%) for 5 min. Following washing, slides
initiated by the addition of [	-32P]ATP, incubated at 30C for 2–4 hr, were stained in alkaline silver iodide for 1 min, followed by washing
and terminated by transferring an aliquot onto P81 phosphocellulose in acetic acid (0.5%) and were then developed (4–10 min). Slides
squares. were then washed and placed in gold chloride (0.1%) for 2 min and
sodium thiosulphate (10%) for 2 min. Following counterstaining in
nuclear fast red (0.1%), slides were dehydrated and mounted. TheSemiquantitative Analysis of Phosphorylated Tau
Tissue regions were homogenized using a polytron homogenizer at number of positively stained cells in equivalent brainstem regions
were counted, and results were expressed as number of positivea w/v ratio of 100 mg tissue/ml of 50 mM Tris-buffered saline (TBS),
pH 7.4, containing 2 mM EGTA, 1 mM PMSF, 10 mM sodium fluoride, cells/mm2 (Bancroft and Stevens, 1990).
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Immunofluorescence Characterization of pathology in transgenic mice over-expressing
human genomic and cDNA tau transgenes. Neurobiol. Dis. 7, 87–98.Tissue sections were prepared as described previously and incu-
bated with monoclonal MC1 and either polyclonal cdk5 pY15or gsk3 Flaherty, D.B., Soria, J.P., Tomasiewicz, H.G., and Wood, J.G. (2000).
pY216 primary antibodies. Fluorophore-tagged anti-mouse IgG Phosphorylation of human tau protein by microtubule-associated
(Texas red) and anti-rabbit IgG (FITC) were used to detect MC1 and kinases: GSK3beta and cdk5 are key participants. J. Neurosci. Res.
cdk5 respectively. Samples were viewed with a Leica DM 1 RBE 62, 463–472.
confocal microscope (Leica Camera AG, Solms, Germany). Images
Friedhoff, P., von Bergen, M., Mandelkow, E.M., and Mandelkow,
were acquired with a UV 40 1.25 NA oil PL AP01 objective (Leica)
E. (2000). Structure of tau protein and assembly into paired helical
with pinhole settings at 1 airy unit for all images.
filaments. Biochim. Biophys. Acta 1502, 122–132.
Gotz, J., and Nitsch, R.M. (2001). Compartmentalized tau hyper-
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